authors Winer, EP Hudis, C Burstein, HJ Wolff, AC Pritchard, KI Ingle, JN Chlebowski, RT Gelber, R Edge, SB Gralow, J Cobleigh, MA Mamounas, EP Goldstein, LJ Whelan, Timothy Powles, TJ Bryant, J Perkins, C Perotti, J Braun, S Langer, AS Browman, GP Somerfield, MR
has subject area 1103 Clinical Sciences (FoR) 1112 Oncology and Carcinogenesis (FoR) Aged (MeSH) Aromatase Inhibitors (MeSH) Biomarkers, Tumor (MeSH) Breast Neoplasms (MeSH) Chemotherapy, Adjuvant (MeSH) Female (MeSH) Humans (MeSH) Middle Aged (MeSH) Neoplasm Recurrence, Local (MeSH) Oncology & Carcinogenesis (Science Metrix) Postmenopause (MeSH) Prognosis (MeSH) Randomized Controlled Trials as Topic (MeSH) Receptors, Estrogen (MeSH) Receptors, Progesterone (MeSH) Risk Factors (MeSH)
keywords 1ST-LINE THERAPY ANASTROZOLE ARIMIDEX BONE LOSS DOUBLE-BLIND ESTROGEN FIRST-LINE THERAPY LETROZOLE Life Sciences & Biomedicine Oncology PHASE-III RANDOMIZED-TRIAL Science & Technology TAMOXIFEN THERAPY
